Previous 10 |
Data confirm strong anticancer activity of two lead compounds in CT-01 program Results support advancement of CT-01 compounds towards IND expected in late 2022 WROCŁAW, Poland, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceut...
News, Short Squeeze, Breakout and More Instantly...
Qwest Corporation 7.00% Notes due 2052 Company Name:
CTX Stock Symbol:
NYSE Market:
Lead asset CT-01 on track for clinical trial application authorization in Q3 2023 Collaboration with Ono Pharmaceuticals in neurological diseases progressing according to plan Solid cash position allows cash visibility until at least late 2024 aided by non-dilutive funding and a c...
CT-01 targets 3 well suited proteins including NEK7 with poor prognosis in key liver cancer Strong preclinical data generated with CT-02 against NEK7 CT-05 potential best-in-class profile in high potential / partially de-risked PKCӨ protein pathway Webcast to take...
WROCŁAW, Poland, March 07, 2023 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (“Captor”) (WSE:CTX), a leader in the development of Targeted Protein Degradation (TPD)-based drugs, today announced its strategic objectives for the period 2023 to 2025 aimed at building a clinical ...